Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience

Table 2

Multivariate analysis (OS).

Variable		HR	95% CI
Age (≤50 vs. >50)	0,9238	0,9586	0,4052 to 2,2678
Breast cancer molecular subtype	0,0028	1,7612	1,2174 to 2,5479
Clinical stage (II vs. III)	0,1418	1,5616	0,8643 to 2,8216
Lymphovascular invasion (absent vs. present)	0,2583	1,7129	0,6769 to 4,3347
Ki-67 change (pre- vs. post-NCT)	0,0093	0,4990	0,2962 to 0,8406

OS, overall survival; HR, hazard ratio; CI, confidence interval; NCT, neoadjuvant chemotherapy.